FILTERED RESULTS
FILTERS
Ads Top
DARK MODE
CHART
    Filters
      Symbols
      Sentiment
      Impact
      Search
      FILTERED RESULTS

        

      Upgrade your plan
      Dashboard

      Merck and Daiichi Sankyo Withdraw US BLA for Ifinatamab Deruxtecan in Extensive-Stage SCLC

      Merck & Co., Inc. and Daiichi Sankyo Company, Limited have officially withdrawn their Biologics License Application (BLA) for ifinatamab deruxtecan, a treatment for extensive-stage small cell lung cancer (SCLC), from the U.S. Food and Drug Administration (FDA). This decision comes as the companies reassess their strategy regarding the drug's development and potential market entry.

      The withdrawal of the BLA indicates that Merck and Daiichi Sankyo will not pursue approval for ifinatamab deruxtecan at this time. The companies have not disclosed specific reasons for this decision, nor have they provided details on any future plans for the drug's development. This move may impact ongoing clinical trials and the overall landscape for SCLC treatments in the United States.

      © 2026 KLEA News. All Rights Reserved. This article is provided for informational purposes only. It is not offered or intended to be used as legal, tax, investment, financial, or other advice.

      Source: KLEA News

      .

      Terra Founder Do Kwon Sentenced to 15 Years in Prison for Fraud